Fresenius (NYSE:FMS) business group Fresenius Kabi said today that it plans to invest more than $100 million over the next five years in a Wilson, N.C.-based manufacturing site.
The company’s expansion project is designed to boost the facility’s capacity to produce generic medicines in pre-filled syringes, Fresenius reported.
The expansion is also slated to increase the number of employees at the site from 100 to 500.
Earlier this year, Fresenius announced that its Dilaudid hydromorphone HCl injection is available in 4 different presentations of the Simplest prefilled syringes.
The Simplist syringes have a 2-year shelf life and do not require any assembly or point-of care preparation.
The prefilled syringes sport different colors associated with different dose strengths and are clearly labelled to avoid confusion between hydromorphone and morphine, Fresenius Kabi said.
In December last year, Fresenius Kabi said that it added its heparin sodium injection to the company’s Simplist prefilled syringe portfolio. The prefilled syringe for subcutaneous and intravenous bolus injections expands Fresenius Kabi’s available Heparin formulations.
